IN8bio Announces Advanced Gamma-Delta (?d) T cell Engager (TCE) Platform for Oncology and Autoimmune Diseases [Yahoo! Finance]
IN8bio, Inc. (INAB)
Company Research
Source: Yahoo! Finance
INB-619, a next generation ?d TCE targeting CD19, eradicates B cells in preclinical models, maintaining depletion over time as ?d T cells expand in response to TCE stimulation ?d TCE targets and expands both Vd1+ and Vd2+ T cells, potentially leading to longer lasting immune responses and deeper B cell depletion Unlike traditional TCEs and CAR-T therapies, ?d T cells naturally secrete lower levels of IL-6, potentially reducing the risk of cytokine release syndrome (CRS) and neurotoxicity (ICANs) Access the webcast discussing the novel ?d TCE platform today at 10:30 a.m. ET during the TD Cowen 45 th Annual Health Care Conference NEW YORK, March 03, 2025 (GLOBE NEWSWIRE) -- IN8bio, Inc . (Nasdaq: INAB) , a clinical-stage biopharmaceutic
Read more
Impact Snapshot
Event Time:
INAB
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
INAB alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
INAB alerts
High impacting IN8bio, Inc. news events
Weekly update
A roundup of the hottest topics
INAB
News
- IN8bio to Present New Preclinical Data on Novel Gamma-Delta (?d) T cell Engager Platform for Cancer Immunotherapy at AACR Annual Meeting 2025GlobeNewswire
- IN8bio to Participate at the 11th Annual Immuno-Oncology 360° Conference 2025GlobeNewswire
- IN8bio, Inc. (NASDAQ: INAB) had its price target lowered by analysts at HC Wainwright from $8.00 to $6.00. They now have a "buy" rating on the stock.MarketBeat
- IN8bio Reports Fourth Quarter and Full-Year 2024 Financial Results and Recent Business HighlightsGlobeNewswire
- IN8bio Announces Advanced Gamma-Delta (?d) T cell Engager (TCE) Platform for Oncology and Autoimmune DiseasesGlobeNewswire
INAB
Earnings
- 3/13/25 - Miss
INAB
Analyst Actions
- 2/12/25 - HC Wainwright
INAB
Sec Filings
- 3/17/25 - Form ARS
- 3/17/25 - Form DEFA14A
- 3/17/25 - Form DEF
- INAB's page on the SEC website